15-Dec-2025
AC Immune’s Interim Phase 2 Results Highlight Promising Slowdown in Parkinson’s Disease Progression
Market Chameleon (Fri, 12-Dec 5:32 AM ET)
TipRanks (Thu, 11-Dec 11:35 AM ET)
AC Immune’s Phase 2 Data Suggests Potential to Slow Parkinson’s Progression with ACI-7104.056
Market Chameleon (Thu, 11-Dec 5:32 AM ET)
AC Immune surges on positive mid-stage trial data for Parkinson’s drug
Seeking Alpha News (Thu, 11-Dec 8:02 AM ET)
AC Immune Reports Promising Phase 2 Results for Parkinson’s Therapy
TipRanks (Thu, 11-Dec 7:29 AM ET)
Globe Newswire (Thu, 11-Dec 7:00 AM ET)
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
Globe Newswire (Tue, 11-Nov 7:00 AM ET)
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
Globe Newswire (Tue, 4-Nov 7:00 AM ET)
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
Globe Newswire (Tue, 28-Oct 7:00 AM ET)
Globe Newswire (Fri, 24-Oct 8:53 AM ET)
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Ac Immune SA trades on the NASDAQ stock market under the symbol ACIU.
As of December 15, 2025, ACIU stock price climbed to $3.24 with 920,268 million shares trading.
ACIU has a beta of 1.65, meaning it tends to be more sensitive to market movements. ACIU has a correlation of 0.18 to the broad based SPY ETF.
ACIU has a market cap of $325.33 million. This is considered a Small Cap stock.
Last quarter Ac Immune SA reported $1 million in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-346,000 and exceeded earnings estimates by $.02.
In the last 3 years, ACIU traded as high as $5.14 and as low as $1.43.
The top ETF exchange traded funds that ACIU belongs to (by Net Assets): IBB, DFAS, DFAC, IBBQ, BIB.
ACIU has underperformed the market in the last year with a return of +8.4%, while SPY returned +13.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ACIU shares. However, ACIU has outperformed the market in the last 3 month and 2 week periods, returning +33.3% and +8.4%, while SPY returned +3.8% and -0.4%, respectively. This indicates ACIU has been having a stronger performance recently.
ACIU support price is $2.95 and resistance is $3.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACIU shares will trade within this expected range on the day.
